Kymera Therapeutics (KYMR) Share-based Compensation Growth (3y) (2022 - 2026)

Kymera Therapeutics (KYMR) Share-based Compensation Growth (3y) (2022 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Stock Comp. Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 244.08%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -50.27%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -0.04%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 38.45%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Kymera Therapeutics 10.77 Bn 10.11 Bn - 19.48%

Historic Data

Download Data
DateValue
Mar 31, 2026 19.48%
Sep 30, 2025 100.82%
Jun 30, 2025 17.01%
Mar 31, 2025 21.82%
Dec 31, 2024 -37.10%
Sep 30, 2024 26.31%
Jun 30, 2024 35.80%
Mar 31, 2024 55.68%
Dec 31, 2023 81.36%
Sep 30, 2023 71.07%
Jun 30, 2023 156.31%
Mar 31, 2023 193.55%
Sep 30, 2022 238.50%